Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation
Biomaterials Advances · 2026-08 · 185 · 214853
DOI: 10.1016/j.bioadv.2026.214853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Advances, 2026-08. Verfasst von Yonghua Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou University of Chinese Medicine, Guangzhou, 510010, Guangdong, China; Department of Hematology, General Hospital of Southern Theater Command…. Hauptthemen laut MEDLINE: Indoles, Polymers, Multiple Myeloma, Immunotherapy. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Bureau, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Photothermal therapy (PTT) not only directly eliminates tumors through its photothermal effects but also triggers a critical antitumor immune response. This study created a multifunctional nanoplatform out of biodegradable mesoporous polydopamine (mPDA). By doping manganese ions (Mn2+) to generate mPDA@Mn nanoparticles, the material's photothermal conversion efficiency was greatly improved, as was the efficient loading of the anticancer medication carfilzomib. This system enables precise control over the release of CFZ and Mn2+ under near-infrared (NIR) irradiation, achieving triple synergistic antitumor effects through chemotherapy, photothermal therapy, and immune activation at the tumor site. In vitro experiments demonstrated that the cell membrane-coated CM@mPDA@Mn/CFZ nanosystem exhibits favorable biocompatibility. In a mouse model of multiple myeloma, the combination of this nanosystem with NIR irradiation showed significant synergistic therapeutic efficacy. It not only destroyed tumor cells directly, but it also stimulated dendritic cell (DC) maturation, CD3+ T cell activation, and cytotoxic T lymphocyte (CTL) infiltration, substantially modifying the tumor immune microenvironment. These findings suggest that this triple synergistic method, which combines chemotherapy, photothermal ablation, and immune activation, provides an effective and targeted nanotherapeutic platform for the treatment of multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou University of Chinese Medicine, Guangzhou, 510010, Guangdong, China; Department of Hematology, General Hospital of Southern Theater Command, Guangzhou, 510010, Guangdong, China; The First School of Clinical Me…
- Department of Hematology, General Hospital of Southern Theater Command, Guangzhou, 510010, Guangdong, China.
- Department of Hematology, General Hospital of Southern Theater Command, Guangzhou, 510010, Guangdong, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510010, Guangdong, China.
Förderung
- Guangzhou Municipal Science and Technology Bureau
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Li, Y., Gao, Y., Xiao, Z., Jiang, W., Han, N., He, X., Ouyang, L., & Zhang, P. (2026). Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation. Biomaterials Advances, 185, 214853. https://doi.org/10.1016/j.bioadv.2026.214853
Vancouver
Li Y, Gao Y, Xiao Z, Jiang W, Han N, He X, et al. Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation. Biomaterials Advances. 2026;185:214853. doi:10.1016/j.bioadv.2026.214853
BibTeX
@article{Li2026,
author = {Li, Yonghua and Gao, Yang and Xiao, Zhifang and Jiang, Wenfang and Han, Na and He, Xianjun and Ouyang, Ling and Zhang, Peng},
title = {Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation},
journal = {Biomaterials Advances},
year = {2026},
volume = {185},
pages = {214853},
doi = {10.1016/j.bioadv.2026.214853}
}
EUVIMED